Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

This should be a very interesting poster:

The third poster presentation, “Identification of an intratumoral immune gene signature associated with tumor regression in an axalimogene filolisbac-treated murine HPV+ tumor model,” will include preclinical data regarding molecular biomarkers associated with tumor regression in a murine HPV+ tumor model. It will be presented by Rachelle Kosoff, Ph.D., Senior Scientist in Research at Advaxis.

“Our findings provide important insights into identifying those patients who are benefiting from these treatments,” said Dr. Hayes. “We’re pleased to share our findings with the rest of the community at the International Cancer Immunotherapy Conference as we continue our work to bring new treatment options to patients.”

If AXAL can be made even more effective by helping to predict who may benefit from the treatment, that bodes extremely well for patients and for designing trials.